Details of the Drug Combination

General Information of Drug Combination (ID: DCS27ZC)

Drug Combination Name
ONC201 THZ1
Indication
Disease Entry Status REF
Diffuse intrinsic pontine glioma Investigative [1]
Component Drugs ONC201   DMM5SCF THZ1   DMU10FE
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: DIPG25
Zero Interaction Potency (ZIP) Score: 8.469
Bliss Independence Score: 14.47
Loewe Additivity Score: 6.241
LHighest Single Agent (HSA) Score: 9.192

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of ONC201
Disease Entry ICD 11 Status REF
Endometrial cancer 2C76 Phase 2 [2]
Glioma 2A00.0 Phase 2 [2]
Multiple myeloma 2A83 Phase 2 [2]
Neuroendocrine cancer 2B72.1 Phase 2 [2]
Recurring respiratory infection CA07-CA45 Phase 2 [2]
leukaemia 2A60-2B33 Phase 1/2 [2]
Lymphoma 2A80-2A86 Phase 1/2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
ONC201 Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dopamine D3 receptor (D3R) TT4C8EA DRD3_HUMAN Antagonist [2]
Dopamine receptor (DR) TTWFZ1N NOUNIPROTAC Antagonist [4]
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Antagonist [2]
------------------------------------------------------------------------------------
Indication(s) of THZ1
Disease Entry ICD 11 Status REF
Nasopharyngeal carcinoma 2B6B Investigative [3]
THZ1 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Cyclin-dependent kinase 7 (CDK7) TTQYF7G CDK7_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma.Cancer Res. 2017 Dec 1;77(23):6614-6626.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014 Jul 31;511(7511):616-20.